{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T04:23:19Z","timestamp":1772252599098,"version":"3.50.1"},"reference-count":40,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,9,21]],"date-time":"2022-09-21T00:00:00Z","timestamp":1663718400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100011019","name":"Nemzeti Kutat\u00e1si Fejleszt\u00e9si \u00e9s Innov\u00e1ci\u00f3s Hivatal","doi-asserted-by":"publisher","award":["EFOP-3.6.3-VEKOP-16-2017-00009"],"award-info":[{"award-number":["EFOP-3.6.3-VEKOP-16-2017-00009"]}],"id":[{"id":"10.13039\/501100011019","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002332","name":"Semmelweis Egyetem","doi-asserted-by":"publisher","award":["STIA KF-17\/24\/2017"],"award-info":[{"award-number":["STIA KF-17\/24\/2017"]}],"id":[{"id":"10.13039\/501100002332","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010661","name":"Horizon 2020 Framework Programme","doi-asserted-by":"publisher","award":["739593"],"award-info":[{"award-number":["739593"]}],"id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["por-journal.com"],"crossmark-restriction":true},"short-container-title":["Pathol. Oncol. Res."],"abstract":"<jats:p>\n                    <jats:bold>Background:<\/jats:bold>\n                    Ibrutinib is widely known as an effective and well-tolerated therapeutical choice of the chronic lymphocytic leukaemia (CLL). However, acquired resistance may occur during the treatment, causing relapse. Early detection of ibrutinib resistance is an important issue, therefore we aimed to find phenotypic markers on CLL cells the expression of which may correlate with the appearance of ibrutinib resistance.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Methods:<\/jats:bold>\n                    We examined 28 patients\u2019 peripheral blood (PB) samples (treatment na\u00efve, ibrutinib sensitive, clinically ibrutinib resistant). The surface markers\u2019 expression (CD27, CD69, CD86, CD184, CD185) were measured by flow cytometry. Furthermore, the BTK\n                    <jats:sup>C481S<\/jats:sup>\n                    resistance mutation was assessed by digital droplet PCR. Moreover, the CLL cells\u2019 phenotype of a patient with acquired ibrutinib resistance was observed during the ibrutinib treatment.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Results:<\/jats:bold>\n                    The expression of CD27 (\n                    <jats:italic>p<\/jats:italic>\n                    = 0.030) and CD86 (\n                    <jats:italic>p<\/jats:italic>\n                    = 0.031) became higher in the clinically resistant cohort than in the ibrutinib sensitive cohort. Besides, we found that high CD86 and CD27 expressions were accompanied by BTK\n                    <jats:sup>C481S<\/jats:sup>\n                    mutation. Our prospective study showed that the increase of the expression of CD27, CD69 and CD86 was noticed ahead of the clinical resistance with 3\u00a0months.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusion:<\/jats:bold>\n                    Our study suggests that the changes of the expression of these markers could indicate ibrutinib resistance and the examination of these phenotypic changes may become a part of the patients\u2019 follow-up in the future.\n                  <\/jats:p>","DOI":"10.3389\/pore.2022.1610659","type":"journal-article","created":{"date-parts":[[2022,9,21]],"date-time":"2022-09-21T00:11:30Z","timestamp":1663719090000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Revealing a Phenotypical Appearance of Ibrutinib Resistance in Patients With Chronic Lymphocytic Leukaemia by Flow Cytometry"],"prefix":"10.3389","volume":"28","author":[{"given":"Ferenc","family":"Tak\u00e1cs","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lili","family":"Kotmayer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c1gnes","family":"Czeti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G\u00e1bor","family":"Szal\u00f3ki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tam\u00e1s","family":"L\u00e1szl\u00f3","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G\u00e1bor","family":"Mikala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c1gnes","family":"M\u00e1rk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andr\u00e1s","family":"Masszi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P\u00e9ter","family":"Farkas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M\u00e1rk","family":"Plander","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00falia","family":"Weisinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Judit","family":"Demeter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S\u00e1ndor","family":"Fekete","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L\u00e1szl\u00f3","family":"Szerafin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Be\u00e1ta Margit","family":"De\u00e1k","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erika","family":"Szaleczky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adrienn","family":"Sul\u00e1k","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zita","family":"Borb\u00e9nyi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G\u00e1bor","family":"Barna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,9,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1002\/1097-0142(20010901)92:5<1325::aid-cncr1454>3.0.co;2-e","article-title":"Chronic Lymphocytic Leukemia Incidence Is Substantially Higher Than Estimated from Tumor Registry Data","volume":"92","author":"Zent","year":"2001","journal-title":"Cancer"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.3324\/haematol.2014.107326","article-title":"Chronic Lymphocytic Leukemia in the Elderly: Clinico-Biological Features, Outcomes, and Proposal of a Prognostic Model","volume":"99","author":"Baumann","year":"2014","journal-title":"Haematologica"},{"key":"B3","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1586\/17474086.2014.977862","article-title":"Ibrutinib: a Paradigm Shift in Management of CLL","volume":"7","author":"Badar","year":"2014","journal-title":"Expert Rev Hematol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"2425","DOI":"10.1056\/NEJMoa1509388","article-title":"Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia","volume":"373","author":"Burger","year":"2015","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1056\/NEJMoa1812836","article-title":"Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL","volume":"379","author":"Woyach","year":"2018","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1182\/blood-2016-06-719294","article-title":"Clonal Evolution Leading to Ibrutinib Resistance in Chronic Lymphocytic Leukemia","volume":"129","author":"Ahn","year":"2017","journal-title":"Blood"},{"key":"B7","doi-asserted-by":"publisher","first-page":"11589","DOI":"10.1038\/ncomms11589","article-title":"Clonal Evolution in Patients with Chronic Lymphocytic Leukaemia Developing Resistance to BTK Inhibition","volume":"7","author":"Burger","year":"2016","journal-title":"Nat Commun"},{"key":"B8","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1002\/ijc.32502","article-title":"Dissection of Subclonal Evolution by Temporal Mutation Profiling in Chronic Lymphocytic Leukemia Patients Treated with Ibrutinib","volume":"146","author":"G\u00e1ng\u00f3","year":"2020","journal-title":"Int J Cancer"},{"key":"B9","doi-asserted-by":"publisher","first-page":"e38","DOI":"10.3324\/haematol.2018.202085","article-title":"Spatial Clonal Evolution Leading to Ibrutinib Resistance and Disease Progression in Chronic Lymphocytic Leukemia","volume":"104","author":"Kiss","year":"2019","journal-title":"Haematologica"},{"key":"B10","doi-asserted-by":"publisher","first-page":"2357","DOI":"10.1182\/blood-2017-12-820910","article-title":"Depth and Durability of Response to Ibrutinib in CLL: 5-year Follow-Up of a Phase 2 Study","volume":"131","author":"Ahn","year":"2018","journal-title":"Blood"},{"key":"B11","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1182\/bloodadvances.2019000864","article-title":"Undetectable Peripheral Blood MRD Should Be the Goal of Venetoclax in CLL, but Attainment Plateaus after 24 Months","volume":"4","author":"Lew","year":"2020","journal-title":"Blood Adv"},{"key":"B12","doi-asserted-by":"publisher","first-page":"2810","DOI":"10.1182\/blood.2020010146","article-title":"Measurable Residual Disease Does Not Preclude Prolonged Progression-free Survival in CLL Treated with Ibrutinib","volume":"138","author":"Wang","year":"2021","journal-title":"Blood"},{"key":"B13","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1084\/jem.20171288","article-title":"Functional and Clinical Relevance of VLA-4 (CD49d\/CD29) in Ibrutinib-Treated Chronic Lymphocytic Leukemia","volume":"215","author":"Tissino","year":"2018","journal-title":"J Exp Med"},{"key":"B14","doi-asserted-by":"publisher","first-page":"4087","DOI":"10.1182\/blood.v99.11.4087","article-title":"B-Cell Chronic Lymphocytic Leukemia Cells Express a Surface Membrane Phenotype of Activated, Antigen-Experienced B Lymphocytes","volume":"99","author":"Damle","year":"2002","journal-title":"Blood"},{"key":"B15","doi-asserted-by":"publisher","first-page":"5507","DOI":"10.18632\/oncotarget.6685","article-title":"CD69 Expression Potentially Predicts Response to Bendamustine and its Modulation by Ibrutinib or Idelalisib Enhances Cytotoxic Effect in Chronic Lymphocytic Leukemia","volume":"7","author":"Montraveta","year":"2016","journal-title":"Oncotarget"},{"key":"B16","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1038\/leu.2015.316","article-title":"BTK Inhibition Results in Impaired CXCR4 Chemokine Receptor Surface Expression, Signaling and Function in Chronic Lymphocytic Leukemia","volume":"30","author":"Chen","year":"2016","journal-title":"Leukemia"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1182\/blood-2011-01-332106","article-title":"CXCL13\/CXCR5 Signaling Enhances BCR-Triggered B-Cell Activation by Shaping Cell Dynamics","volume":"118","author":"S\u00e1ez de Guinoa","year":"2011","journal-title":"Blood"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1080\/10428194.2017.1403598","article-title":"Ibrutinib and Idelalisib Block Immunophenotypic Changes Associated with the Adhesion and Activation of CLL Cells in the Tumor Microenvironment","volume":"59","author":"Shen","year":"2018","journal-title":"Leuk Lymphoma"},{"key":"B19","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1007\/s12253-018-0512-7","article-title":"The Effect of CD86 Expression on the Proliferation and the Survival of CLL Cells","volume":"25","author":"Tak\u00e1cs","year":"2019","journal-title":"Pathol Oncol Res"},{"key":"B20","doi-asserted-by":"publisher","first-page":"3747","DOI":"10.1002\/eji.201344421","article-title":"AID Induces Intraclonal Diversity and Genomic Damage in CD86(+) Chronic Lymphocytic Leukemia Cells","volume":"44","author":"Huemer","year":"2014","journal-title":"Eur J Immunol"},{"key":"B21","article-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","volume-title":"World Health Organization Classification of Tumours","author":"Bosman","year":"2017"},{"key":"B22","doi-asserted-by":"publisher","first-page":"2745","DOI":"10.1182\/blood-2017-09-806398","article-title":"iwCLL Guidelines for Diagnosis, Indications for Treatment, Response Assessment, and Supportive Management of CLL","volume":"131","author":"Hallek","year":"2018","journal-title":"Blood"},{"key":"B23","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1080\/0284186X.2021.1878388","article-title":"Identification of a Novel Resistance Mechanism in Venetoclax Treatment and its Prediction in Chronic Lymphocytic Leukemia","volume":"60","author":"Tak\u00e1cs","year":"2021","journal-title":"Acta Oncol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1111\/bjh.17502","article-title":"Screening and Monitoring of the BTK(C481S) Mutation in a Real-World Cohort of Patients with Relapsed\/refractory Chronic Lymphocytic Leukaemia during Ibrutinib Therapy","volume":"194","author":"Bodor","year":"2021","journal-title":"Br J Haematol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1158\/2159-8290.CD-18-1119","article-title":"Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia","volume":"9","author":"Blombery","year":"2019","journal-title":"Cancer Discov"},{"key":"B26","doi-asserted-by":"publisher","first-page":"894","DOI":"10.3389\/fonc.2020.00894","article-title":"Resistance-Associated Mutations in Chronic Lymphocytic Leukemia Patients Treated with Novel Agents","volume":"10","author":"Sedlarikova","year":"2020","journal-title":"Front Oncol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1182\/blood-2018-01-824177","article-title":"MRD Negativity as a Surrogate for PFS in CLL?","volume":"131","author":"Thompson","year":"2018","journal-title":"Blood"},{"key":"B28","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/s41467-019-14081-6","article-title":"Chromatin Mapping and Single-Cell Immune Profiling Define the Temporal Dynamics of Ibrutinib Response in CLL","volume":"11","author":"Rendeiro","year":"2020","journal-title":"Nat Commun"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.4161\/onci.21425","article-title":"Modulating CD27 Signaling to Treat Cancer","volume":"1","author":"Riether","year":"2012","journal-title":"Oncoimmunology"},{"key":"B30","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1182\/blood-2006-03-011759","article-title":"ZAP-70 Enhances B-Cell-Receptor Signaling Despite Absent or Inefficient Tyrosine Kinase Activation in Chronic Lymphocytic Leukemia and Lymphoma B Cells","volume":"109","author":"Gobessi","year":"2007","journal-title":"Blood"},{"key":"B31","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1016\/j.leukres.2015.04.016","article-title":"Differential Expression and Function of CD27 in Chronic Lymphocytic Leukemia Cells Expressing ZAP-70","volume":"39","author":"Lafarge","year":"2015","journal-title":"Leuk Res"},{"key":"B32","doi-asserted-by":"publisher","first-page":"279","DOI":"10.3324\/haematol.2011.052829","article-title":"CD69 Is Independently Prognostic in Chronic Lymphocytic Leukemia: a Comprehensive Clinical and Biological Profiling Study","volume":"97","author":"Del Poeta","year":"2012","journal-title":"Haematologica"},{"key":"B33","doi-asserted-by":"publisher","first-page":"3286","DOI":"10.1182\/blood-2014-02-548610","article-title":"Ibrutinib Inhibits BCR and NF-\u03baB Signaling and Reduces Tumor Proliferation in Tissue-Resident Cells of Patients with CLL","volume":"123","author":"Herman","year":"2014","journal-title":"Blood"},{"key":"B34","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1007\/s12185-009-0320-7","article-title":"Defective Expression and Modulation of B7-2\/CD86 on B Cells in B Cell Chronic Lymphocytic Leukemia","volume":"89","author":"Dai","year":"2009","journal-title":"Int J Hematol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s12865-020-00343-2","article-title":"A Combination of the Activation Marker CD86 and the Immune Checkpoint Marker B and T Lymphocyte Attenuator (BTLA) Indicates a Putative Permissive Activation State of B Cell Subtypes in Healthy Blood Donors Independent of Age and Sex","volume":"21","author":"Axelsson","year":"2020","journal-title":"BMC Immunol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"3367","DOI":"10.1182\/blood-2009-06-225326","article-title":"The Microenvironment in Mature B-Cell Malignancies: a Target for New Treatment Strategies","volume":"114","author":"Burger","year":"2009","journal-title":"Blood"},{"key":"B37","doi-asserted-by":"publisher","first-page":"e45185","DOI":"10.1371\/journal.pone.0045185","article-title":"CD80 and CD86 Differentially Regulate Mechanical Interactions of T-Cells with Antigen-Presenting Dendritic Cells and B-Cells","volume":"7","author":"Lim","year":"2012","journal-title":"PLoS One"},{"key":"B38","doi-asserted-by":"publisher","first-page":"3052","DOI":"10.1172\/JCI89756","article-title":"Ibrutinib Treatment Improves T Cell Number and Function in CLL Patients","volume":"127","author":"Long","year":"2017","journal-title":"J Clin Invest"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1182\/blood-2002-06-1822","article-title":"Differential Signaling via Surface IgM Is Associated with VH Gene Mutational Status and CD38 Expression in Chronic Lymphocytic Leukemia","volume":"101","author":"Lanham","year":"2003","journal-title":"Blood"},{"key":"B40","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1038\/nature11309","article-title":"Chronic Lymphocytic Leukaemia Is Driven by Antigen-independent Cell-Autonomous Signalling","volume":"489","author":"D\u00fchren-von Minden","year":"2012","journal-title":"Nature"}],"container-title":["Pathology and Oncology Research"],"original-title":[],"link":[{"URL":"https:\/\/www.por-journal.com\/articles\/10.3389\/pore.2022.1610659\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,21]],"date-time":"2022-09-21T00:11:35Z","timestamp":1663719095000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.por-journal.com\/articles\/10.3389\/pore.2022.1610659\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,21]]},"references-count":40,"alternative-id":["10.3389\/pore.2022.1610659"],"URL":"https:\/\/doi.org\/10.3389\/pore.2022.1610659","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-1554274\/v1","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-1046046\/v1","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-1046046\/v2","asserted-by":"object"}]},"ISSN":["1532-2807"],"issn-type":[{"value":"1532-2807","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,21]]},"article-number":"1610659"}}